HERE’S TO 5 YEARS SINCE INITIAL FDA APPROVAL FOR ADULT PATIENTS (18+ YEARS) WITH UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS.a

a FDA approved since 2017 for adults, 2019 for teens (aged 12-17 years) and 2020 for children (aged 6-11 years) and 2022 for young children (aged 6 months-5 years) with uncontrolled moderate-to-severe atopic dermatitis.

DUP.22.06.0381

A BREAKTHROUGH BIOLOGIC
TREATMENT FOR ECZEMA

DUPIXENT helps block a key source of inflammation that can cause eczema

DUPIXENT helps you stay ahead of symptoms by continuously treating eczema, even between flare-ups

A close up look of normal skin cells
Normal Skin

A healthy immune
system
produces little to
no inflammation on the
skin.

A close up look of skin cells with Uncontrolled Moderate-to-Severe Eczema (Atopic Dermatitis)
Skin With Eczema

The immune system in
those with eczema may
produce more
inflammation than
normal, contributing to
itching, rashes, and
flare-ups on the surface
of the skin.

Close view of skin cells treated with Dupixent® (dupilumab) for Uncontrolled Moderate-to-Severe Eczema (Atopic Dermatitis)
Eczema Skin Treated
With DUPIXENT

DUPIXENT may help reduce this inflammation in those with uncontrolled moderate-to-severe eczema for noticeably clearer skin and less itch.

A DIFFERENCE
INSIDE AND OUT

  • A BIOLOGIC that continuously treats eczema from the inside, even between flare-ups
  • NOT A STEROID or immunosuppressant
  • TREATS BOTH moderate and severe eczema when topical prescription therapies aren't enough
  • DOES NOT REQUIRE initial or routine bloodwork (according to Prescribing Information)
  • Can be used with or without topical corticosteroids
  • IS NOT TAKEN DAILY

SEE HOW DUPIXENT WORKS TO TREAT ECZEMA